{
    "clinical_study": {
        "@rank": "133000", 
        "acronym": "STAFE", 
        "arm_group": [
            {
                "arm_group_label": "Biomarker group", 
                "arm_group_type": "Experimental", 
                "description": "Intervention group, in which the duration of empirical antifungal therapy will be based on the results of biomarkers.\nBiomarker group"
            }, 
            {
                "arm_group_label": "Control group", 
                "arm_group_type": "No Intervention", 
                "description": "Control group, in which the duration of empirical antifungal therapy will be based on international recommendations (14 days)."
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators hypothesized that the use of biomarkers of invasive fungal infections\n      would increase the percentage of early discontinuation of empirical antifungal therapy and\n      thus reduce the duration of treatment in ICU patients."
        }, 
        "brief_title": "Fungal Biomarkers to Reduce Duration of Empirical Antifungal Therapy: a Randomized Comparative Study (STAFE)", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Fungal Infection", 
            "Critical Illness"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Critical Illness", 
                "Mycoses"
            ]
        }, 
        "detailed_description": {
            "textblock": "The duration of empirical/preemptive anti fungal treatment will be based in the intervention\n      group on biomarker results.\n\n      Biomarkers of fungal disease will performed before starting anti fungal treatment and at day\n      4."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age > or = 18 years\n\n          -  Patients requiring empiric antifungal therapy the first time in the ICU\n\n          -  Predictable duration of hospitalization in the ICU \u2265 6 days\n\n        Exclusion Criteria:\n\n          -  Neutropenia (WBC <1000 or neutrophils <500/mm3)\n\n          -  Immunosuppressive therapy (chemotherapy within 3 months prior to the ICU admission,\n             solid organ graft under immunosuppressive therapy)\n\n          -  invasive fungal infection documented in the three previous months\n\n          -  Antifungal treatment in the three previous months\n\n          -  Pregnant or lactating women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "110", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02154178", 
            "org_study_id": "2013 A00756 39"
        }, 
        "intervention": {
            "arm_group_label": "Biomarker group", 
            "description": "use of invasive fungal disease biomarkers (\u03b2-1,3-glucan, mannan/anti-mannan antibodies)", 
            "intervention_name": "Biomarker group", 
            "intervention_type": "Other", 
            "other_name": "intervention group"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antifungal Agents", 
                "Clotrimazole", 
                "Miconazole"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "empiric antifungal therapy", 
            "biomarkers", 
            "invasive fungal infection", 
            "Candida"
        ], 
        "lastchanged_date": "May 29, 2014", 
        "location": {
            "contact": {
                "email": "s-nseir@chru-lille.fr", 
                "last_name": "Saad Nseir, MD, PhD", 
                "phone": "0033320444084"
            }, 
            "facility": {
                "address": {
                    "city": "Lille", 
                    "country": "France", 
                    "state": "Nord", 
                    "zip": "59035"
                }, 
                "name": "ICU, Salengro Hospital, University Hospital of Lille"
            }, 
            "investigator": {
                "last_name": "Saad Nseir, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Fungal Biomarkers to Reduce Duration of Empirical Antifungal Therapy: a Randomized Comparative Study", 
        "overall_contact": {
            "email": "saadalla.nseir@chru-lille.fr", 
            "last_name": "Saad nseir, MD", 
            "phone": "0033320444084"
        }, 
        "overall_official": {
            "affiliation": "Univ Hosp of Lille, France", 
            "last_name": "Saad Nseir, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Early discontinuation is defined as discontinuation of anti fungal treatment before the 7th day after the start of treatment", 
            "measure": "percentage of early discontinuation of empiric antifungal therapy", 
            "safety_issue": "No", 
            "time_frame": "7 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02154178"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Hospital, Lille", 
            "investigator_full_name": "Saad NSEIR", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "death during the 28 days following ICU admission", 
                "measure": "mortality in ICU", 
                "safety_issue": "No", 
                "time_frame": "28 days after ICU admission"
            }, 
            {
                "description": "mechanical ventilation duration during the 28 days following ICU admission", 
                "measure": "duration of mechanical ventilation and ICU stay", 
                "safety_issue": "No", 
                "time_frame": "28 days after ICU admission"
            }, 
            {
                "description": "Any fungal colonization or infection diagnosed during the 28 days following ICU admission", 
                "measure": "fungal colonization / infection after antifungal therapy, with or without resistant strains", 
                "safety_issue": "No", 
                "time_frame": "28 days after ICU admission"
            }
        ], 
        "source": "University Hospital, Lille", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Lille", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}